Locoregional Cutaneous Metastases of Malignant Melanoma and their Management

Dermatologic Surgery

Volumn 30, Issue 2 II, 2004, Pages 244-247

  Wolf, Ingrid H ^a   Richtig, Erika ^a   Kopera, Daisy ^a   Kerl, Helmut ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CISPLATIN; DACARBAZINE; IMIQUIMOD; INTERLEUKIN 2;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CRYOTHERAPY; ELECTROSURGERY; GENE THERAPY; HUMAN; LASER SURGERY; LYMPH NODE METASTASIS; MELANOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN METASTASIS;

EID: 1542288810     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200402002-00003     Document Type: Review

References (27)

1. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001;19:3635-48.
2. Roses DF, Harris MN, et al. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-9.
3. Reintgen DS, Cox C, Slingluff CL Jr., Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992;28:45-9.
4. Ames FC, Balch CM, Reintgen D. Local recurrences and their management. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott, 1992:287-94.
5. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94-8.
6. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, et al. Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study. Cancer 1997;80:1418-25.
7. Kretschmer L, Preusser K-P, Neumann C. Locoregional cutaneous metastasis in patients with therapeutic lymph node dissection for malignant melanoma: risk factors and prognostic impact. Melanoma Res 2002;12:499-504.
8. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time: courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70.
9. Ackerman AB, Cerroni L, Kerl H. Pitfalls in Histopathologic Diagnosis of Malignant Melanoma. Philadelphia: Lea & Febiger, 1994.
10. Gerbe C, Cerroni L, Kerl H. Melanozytaere naevi und malignes melanom. In: Kerl H, Garbe C, Cerroni L, et al., eds. Histopathologie der Haut. Berlin: Springer, 2003:593-649.
11. Heenan PJ. Local recurrence of melanoma. Australas J Dermatol 1997;38(Suppl):S59-S62.
12. Yu LL, Heenan PJ. The morphological features of locally recurrent melanoma and cutaneous metastases of melanoma. Hum Pathol 1999;30:551-5.
13. Issels R. Hyperthermia combined with chemotherapy: biological rationale, clinical application, and treatment results. Onkologie 1999;22:374-81.
14. Oratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003;13:59-66.
15. Karrer S, Szeimies R-M, Hohenleutner U, Landthaler M. Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol 2001;2:229-37.
16. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135-8.
17. Ugurel S, Wagner A, Pfoehler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002;147:621-4.
18. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-6.
19. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571-7.
20. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol 2002;147:1-6.
21. Hengge UR, Esser S, Schultewolter T, et al. Self-administrated topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000;143:1026-31.
22. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001;144:1050-3.
23. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001;27:561-4.
24. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
25. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6.
26. Nestle FO. Vaccines and melanoma. Clin Exp Dermatol 2002;27:597-601.
27. Cascinelli N, Heerlyn M, Schneeberger A, et al. What is the most promising strategy for the treatment of metastasizing melanoma? Exp Dermatol 2000;9:439-51.